You have 9 free searches left this month | to do more

niraparib

Niraparib is a drug used to treat Ovarian Cancer, Ovarian Neoplasms, Fallopian Tube Cancer, and other conditions. Niraparib is being actively studied in 82 studies and prior, has been studied in 12.

Top SponsorsTop SitesTop Investigators
Tesaro, Inc.GSK Investigational SiteAlice Ho
Janssen Research & Development, LLCCentre Leon BerardAntoinette Tan, MD
Massachusetts General HospitalDana-Farber Cancer InstituteBeihua Kong
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
A
Not yet recruiting
  • Ovarian Cancer
  • +2 more
  • (no location specified)
2021-08-10
Aug 10, 2021
E
Withdrawn
  • Advanced Solid Tumor
  • Breast Cancer
  • (no location specified)
2021-06-24
Jun 24, 2021
T
Completed
  • Advanced Solid Tumors
  • Niraparib
  • Chuo-ku, Tokyo, Japan
    National Cancer Center Hospital
2021-10-12
Oct 12, 2021
L
Not yet recruiting
  • Epithelial Ovarian Cancer
  • Niraparib
  • (no location specified)
2021-07-23
Jul 23, 2021
A
Withdrawn
  • Breast Cancer
  • Niraparib
  • +5 more
  • (no location specified)
2021-05-30
May 30, 2021
C
Recruiting
  • Metastatic Melanoma
  • Niraparib
  • San Francisco, California
    California Pacific Medical Center Research Institute
2021-10-15
Oct 15, 2021
T
Recruiting
  • Recurrent Glioblastoma
  • Niraparib
  • Tianjin, Tianjin, China
    Tianjin Huanhu Hosptal
2021-01-18
Jan 18, 2021
W
Recruiting
  • HRD
  • +2 more
  • Atlanta, Georgia
    Winship Cancer Institute of Emory University
2021-10-19
Oct 19, 2021
G
Recruiting
  • Ovarian Neoplasms
  • Breast Neoplasms
  • Niraparib
  • Tucson, Arizona
  • +9 more
2021-10-03
Oct 3, 2021
T
Recruiting
  • Ovarian Cancer
  • Niraparib
  • Hong Kong, Hong Kong
    The University of Hong Kong
2021-09-27
Sep 27, 2021
K
Completed
  • Ovarian Cancer
  • Peritoneal Cancer
  • Niraparib
  • Oslo, Norway
    Oslo University Hospital (OUH)
2021-03-02
Mar 2, 2021
M
Not yet recruiting
  • Metastatic Cancer
  • Central Nervous System Cancer
  • Niraparib
  • Boston, Massachusetts
  • +2 more
2021-07-28
Jul 28, 2021
T
Suspended
  • Breast Cancer
  • Niraparib
  • Amsterdam, Netherlands
  • +2 more
2021-10-18
Oct 18, 2021
A
Active, not recruiting
  • Breast Cancer
  • Ovarian Cancer
  • Sioux Falls, South Dakota
    Avera Cancer Institute
2021-08-24
Aug 24, 2021
A
Not yet recruiting
  • Recurrent Ovarian Cancer
  • +2 more
  • (no location specified)
2021-11-16
Nov 16, 2021
T
Recruiting
  • Ovarian Cancer
  • Niraparib
  • Tokyo, Japan
    Takeda Selected Site
2021-10-12
Oct 12, 2021
M
Active, not recruiting
  • Pancreatic Cancer
  • Metastatic Pancreatic Cancer
  • Niraparib
  • +2 more
  • Boston, Massachusetts
  • +2 more
2021-10-18
Oct 18, 2021
D
Recruiting
  • Pancreatic Cancer
  • Niraparib
  • Boston, Massachusetts
  • +2 more
2021-05-12
May 12, 2021
T
Recruiting
  • Head and Neck Cancer
  • Cincinnati, Ohio
  • +1 more
2021-09-15
Sep 15, 2021
M
Recruiting
  • Triple Negative Breast Cancer
  • Residual Disease
  • Niraparib
  • Radiation Therapy
  • Boston, Massachusetts
  • +1 more
2021-10-27
Oct 27, 2021
G
Recruiting
  • Solid Tumor, Adult
  • Homologous Recombination Deficiency
  • Washington, District of Columbia
  • +2 more
2021-08-31
Aug 31, 2021
S
Not yet recruiting
  • Platinum-resistant Recurrent Clear Cell Ovarian Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2021-11-21
Nov 21, 2021
E
Recruiting
  • Advanced Microsatellite Stable Colorectal Carcinoma
  • +5 more
  • Niraparib
  • Panitumumab
  • Atlanta, Georgia
  • +2 more
2021-10-29
Oct 29, 2021
U
Recruiting
  • ATM Gene Mutation
  • +16 more
  • Niraparib
  • +2 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
2021-04-06
Apr 6, 2021